Literature DB >> 26843102

Rivaroxaban: can we trust the evidence?

Deborah Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26843102     DOI： 10.1136/bmj.i575

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice?

Authors:  Jason D Matos; Peter J Zimetbaum
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

Review 2.  Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?

Authors:  Paul P Dobesh; John Fanikos
Journal:  J Atr Fibrillation       Date:  2016-08-31

3.  Drug therapy in anticoagulation: which drug for which patient?

Authors:  Carolyn M Millar; Mike A Laffan
Journal:  Clin Med (Lond)       Date:  2017-06       Impact factor: 2.659

Review 4.  Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.

Authors:  Faye L Norby; Alvaro Alonso
Journal:  J Comp Eff Res       Date:  2017-07-24       Impact factor: 1.744

5.  Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.

Authors:  Alma R Oskarsdottir; Brynja R Gudmundsdottir; Hulda M Jensdottir; Bjorn Flygenring; Ragnar Palsson; Pall T Onundarson
Journal:  Blood       Date:  2021-05-20       Impact factor: 22.113

6.  Novel Oral Anticoagulants for Venous Thromboembolism with Special Emphasis on Risk of Hemorrhagic Complications and Reversal Agents.

Authors:  Zaheer Ahmed; Seemeen Hassan; Gary A Salzman
Journal:  Curr Drug ther       Date:  2016-04

7.  Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.

Authors:  Faye L Norby; Lindsay G S Bengtson; Pamela L Lutsey; Lin Y Chen; Richard F MacLehose; Alanna M Chamberlain; Ian Rapson; Alvaro Alonso
Journal:  BMC Cardiovasc Disord       Date:  2017-09-06       Impact factor: 2.298

8.  ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.

Authors:  Nadia Aspromonte; Michele Massimo Gulizia; Aldo Clerico; Giuseppe Di Tano; Michele Emdin; Mauro Feola; Massimo Iacoviello; Roberto Latini; Andrea Mortara; Roberto Valle; Gianfranco Misuraca; Claudio Passino; Serge Masson; Alberto Aimo; Marcello Ciaccio; Marco Migliardi
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

Review 9.  Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta-Analyses of Observational Studies.

Authors:  Anneka Mitchell; Margaret C Watson; Tomas Welsh; Anita McGrogan
Journal:  J Clin Med       Date:  2019-04-24       Impact factor: 4.241

10.  Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Authors:  Torben Bjerregaard Larsen; Flemming Skjøth; Peter Brønnum Nielsen; Jette Nordstrøm Kjældgaard; Gregory Y H Lip
Journal:  BMJ       Date:  2016-06-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.